BCAB Message Board Post 10058658 | BioAtla Inc.
home / stock / bcab / bcab message board
Bjohnson704
(investorshub)
Posted on: Nov/04/2022 13:01:55
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170368232
BioAtla Reports Q3 2022 Cash Balance Of $178.1M
News, Short Squeeze, Breakout and More Instantly...
-
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day ar...
-
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...
-
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with PD1 are associated with manageable safety w...